To evaluate this distribution, a phantom study was done.
The aim of the present study was to investigate in a prospective trial the potential merit of measuring concentrations of PTN in patients with lung cancer, by evaluating the distribution of this recently described angiogenic factor in comparison to that of the classical angiogenic growth factor, VEGF.
We employed this metric in evaluating the distribution of wood within 17 streams in two regions of northeastern North America.
We present a modified version of a previously described metric used to quantify the spatial extent and pattern of instream wood distribution, then apply this approach in evaluating the distribution of wood habitat in forested northeastern North American streams.
After considering this analysis and evaluating the distribution of the remaining common items along the difficulty range of the test and the items' representativeness of the test content, six items were selected to equate the TRC-n-2 and TRC-n-3 test forms: RB1LC, RB2LC, RB3.6IC, RB3.10IC, AN3.9CC and TT6IC.
This study thus provides, for the first time, a comprehensive perspective on the extent of sex chromosome divergence in this species by evaluating the distribution of homozygous and heterozygous genotypes, molecular evolution, and gene expression of sex chromosomes in the context of the rest of the genome.
Moreover, we investigated this directly by evaluating the distribution of interaction degree normalized by the total number of interactions in datasets rich in membrane interactions (e.g., PF-PCA and SU-2HY, both with more than 65% membrane interactions) or with a poor coverage of membrane interactions (e.g., two hybrid (2HY), (29%) and affinity capture-MS (14%)).
This would further help in evaluating the distribution and chemical character of the mineral matter occurring within the maceral types.
We explored the distribution of base excess (BE) values in a large number of ICU patients and evaluated if this distribution was related to rising sodium values after admission.
To evaluate, if this distribution and in particular the incidence of blood group 0 differed from that of a patient cohort without pancreatic cancer, we enrolled a control group of 13.044 patients who were treated at the Department of Surgery, University of Heidelberg for diagnoses other than pancreatic cancer during the same period of time (October 2001 until December 2008).
